Activation of platelet-rich plasma using thrombin receptor agonist peptide
Activation of platelet-rich plasma using thrombin receptor agonist peptide
复制标题
DOI：
10.1016/j.joms.2004.12.007
复制
发表时间：
2005-04-01
影响因子：
1.9
通讯作者：
Lu, HH
中科院分区：
文献类型：
--
作者：
Landesberg, R;Burke, A;Lu, HH
目的：本研究提出了一种制备富血小板血浆（PRP）的替代方法。具体而言，我们比较使用凝血酶受体激动剂肽6（TRAP）和牛凝血酶作为凝血剂在制备PRP。材料和方法：PRP通过离心和凝血酶或TRAP凝块制备。监测作为TRAP浓度的函数的体外凝血时间，并且通过测量随时间推移的凝块直径来确定凝块收缩。在优化TRAP浓度后，添加几种市售骨替代物重复实验。PRP相关生长因子的释放作为PRP preparation.Results的函数也被determined：PRP的最快速的聚合发生与凝血酶的加入，其次是TRAP/Allogro（Ceramed，莱克伍德，CO），TRAP/BioGlass（Mo-Sci，Rolla，MN），TRAP/BioOss（Osteohealth，雪莉，纽约州），和TRAP单独。凝血酶引起相当大的凝块收缩（43%），而TRAP单独导致只有15%的收缩。TRAP/Allogro、TRAP/BioOss和TRAP/BioGlass均表现出最小的回缩（8%）。结论：在制备PRP时使用TRAP激活凝块形成可能是牛凝血酶的安全替代品。与目前可用的PRP生产方法相比，它具有出色的工作时间和显著更少的凝块收缩。(c)2005年美国口腔颌面外科医师协会。
Purpose: This study proposes an alternative preparation method of platelet-rich plasma (PRP). Specifically, we compare the use of thrombin receptor agonist peptitle-6 (TRAP) and bovine thrombin as a clotting agent in the preparation of PRP.Materials and Methods: PRP was prepared by centrifugation and clotted with thrombin or TRAP. In vitro clotting times were monitored as a function of TRAP concentration, and clot retraction was determined by measuring clot diameter over time. Following the optimization of TRAP concentration, experiments were repeated with the addition of several commercially available bone substitutes. The release of PRP-relevant growth factors as a function of PRP preparation was also determined.Results: The most rapid polymerization of PRP takes place with the addition of thrombin, followed by TRAP/Allogro (Ceramed, Lakewood, CO), TRAP/BioGlass (Mo-Sci, Rolla, MN), TRAP/BioOss (Osteohealth, Shirley, NY), and TRAP alone. Thrombin caused considerable clot retraction (43%), whereas TRAP alone resulted in only 15% retraction. TRAP/Allogro, TRAP/BioOss, and TRAP/BioGlass all exhibited minimal retraction (8%).Conclusions: The use of TRAP to activate clot formation in the preparation of PRP may be a safe alternative to bovine thrombin. It results in an excellent working time and significantly less clot retraction than the currently available methods of PRP production. (c) 2005 American Association of Oral and Maxillofacial Surgeons.